Allergan to Vigorously Defend Frivolous Lawsuit Against BOTOX; Stands Behind Established 20-Year Safety Profile of BOTOX.

Business Editors & Health/Medical Writers

IRVINE, Calif.--(BUSINESS WIRE)--Feb. 4, 2003

Allergan, Inc. (NYSE:AGN) said today that it is aware of and finds no validity in a lawsuit filed against it by a California couple. A physician was also named in the lawsuit.

"We have reviewed the complaint and reject the allegations and this lawsuit as frivolous," said Douglas S. Ingram, Corporate Vice President and General Counsel. "Allergan stands behind the well-established safety record of BOTOX(R). We intend to aggressively defend our product in Court and do not intend to resolve this matter short of complete vindication."

"BOTOX(R) has an extraordinary 20-year safety history and has improved the lives of over a million people around the world, many suffering from debilitating conditions such as cervical dystonia, juvenile cerebral palsy, strabismus (crossed eyes), and blepharospasm (uncontrollable blinking). The allegations in the claim are completely inconsistent with this extensive safety profile," continued Ingram. "BOTOX(R) has been commercially available in the U.S. since 1989. It is unfortunate, but not entirely unexpected, that someone might eventually decide to use a legal claim as a tactic for financial gain. We will, however, vigorously defend this lawsuit and the long-standing reputation of this exceptional product."

BOTOX(R) and BOTOX(R) Cosmetic are currently approved for marketing in the United States. BOTOX(R) therapy carries the unique distinction of being the only product of its kind with over 20 years experience in development and successful clinical practice in people worldwide. It is currently approved in more than 70 countries for a broad range of neurological and aesthetic conditions including cervical dystonia, juvenile cerebral palsy, strabismus (crossed eyes), blepharospasm (uncontrollable blinking) and glabellar lines. In the United States, BOTOX(R) has been approved since 1989 and is in clinical trials for the treatment of hyperhidrosis (excessive sweating), post-stroke spasticity and headache.

Forward-Looking Statements

This press release contains "forward-looking statements," including, but not limited to, statements regarding the possible outcomes of the litigation and appeal process. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks include the inherent uncertainties associated with litigation and the litigation process in the United States. The reader is thus cautioned not to rely on these forward-looking statements. Additional information concerning these and other risk factors can be found in press releases issued by Allergan as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading " Certain Factors and Trends Affecting Business" in Allergan's 2001 Form 10-K and its Form 10-Q for the quarter ended September 27, 2002. Copies of Allergan press releases and additional information about Allergan are available on the World Wide Web at www.allergan.com, or you can contact the Allergan Investor Relations Department by calling 714-246-4636.

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator and skin care markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives.